These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38581995)

  • 1. Impact of Drp1-regulated changes in T cell activity on the combined antitumor effects of PARPi and PD-1 inhibitors.
    Ma J; Song J; Yi X; Zhang S; Huang L; Sun L; Gao R; Han C
    Int Immunopharmacol; 2024 May; 132():112006. PubMed ID: 38581995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced T cell immune activity mediated by Drp1 promotes the efficacy of PD-1 inhibitors in treating lung cancer.
    Ma J; Song J; Yi X; Zhang S; Sun L; Huang L; Han C
    Cancer Immunol Immunother; 2024 Feb; 73(2):40. PubMed ID: 38340166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 4. PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures.
    Appleton KM; Elrod AK; Lassahn KA; Shuford S; Holmes LM; DesRochers TM
    Cancer Immunol Immunother; 2021 Mar; 70(3):843-856. PubMed ID: 33492447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niraparib enhances antitumor immunity and contributes to the efficacy of PD-L1 blockade in cervical cancer.
    Chang J; Quan S; Tian S; Wang S; Li S; Guo Y; Yang T; Yang X
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):304. PubMed ID: 38869633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
    Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
    J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.
    Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J
    Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Gupta T; Vinayak S; Telli M
    Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.
    Wang Y; Zheng K; Xiong H; Huang Y; Chen X; Zhou Y; Qin W; Su J; Chen R; Qiu H; Yuan X; Wang Y; Zou Y
    Front Immunol; 2021; 12():762989. PubMed ID: 34975854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
    Dammeijer F; van Gulijk M; Mulder EE; Lukkes M; Klaase L; van den Bosch T; van Nimwegen M; Lau SP; Latupeirissa K; Schetters S; van Kooyk Y; Boon L; Moyaart A; Mueller YM; Katsikis PD; Eggermont AM; Vroman H; Stadhouders R; Hendriks RW; Thüsen JV; Grünhagen DJ; Verhoef C; van Hall T; Aerts JG
    Cancer Cell; 2020 Nov; 38(5):685-700.e8. PubMed ID: 33007259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer.
    Zhou L; Xu Q; Huang L; Jin J; Zuo X; Zhang Q; Ye L; Zhu S; Zhan P; Ren J; Lv T; Song Y
    Cancer Lett; 2021 Mar; 500():163-171. PubMed ID: 33278498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in non-small cell lung cancer harbouring driver mutations.
    Addeo A; Passaro A; Malapelle U; Banna GL; Subbiah V; Friedlaender A
    Cancer Treat Rev; 2021 May; 96():102179. PubMed ID: 33798954
    [No Abstract]   [Full Text] [Related]  

  • 18. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
    Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
    Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.